{
  "docId": "019de075-b6c3-715f-bed8-4c3a534b1fd4",
  "docSlug": "88f1b85a63c225232d32e053da178119",
  "documentTitle": "Mainz Biomed NV | Investor Presentation Deck | 25 slides",
  "authorId": "mainz-biomed-nv",
  "authorName": "Mainz Biomed",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 25,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-b6c3-715f-bed8-4c3a534b1fd4/3",
  "deckHref": "/decks/019de075-b6c3-715f-bed8-4c3a534b1fd4",
  "deckJsonHref": "/decks/019de075-b6c3-715f-bed8-4c3a534b1fd4.json",
  "deckAnchorHref": "/decks/019de075-b6c3-715f-bed8-4c3a534b1fd4#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.7,
        "y": 0.55
      },
      "kind": "list",
      "text": "Strong team\nExperienced diagnostics team, formerly Roche, Abbott or Qiagen; took the company public in 2021\n59 employees with headquarters in Mainz, Germany\nStrong Medical Advisory Board with renowned scientific and oncology experts",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e0f36cc-f323-4b2f-a11f-8c5afd5d3edb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.7,
        "y": 0.0016
      },
      "kind": "list",
      "text": "Disruptive, decentralized business model\nKit-based solution that allows the testing to be done in any lab\nCompetitors like Exact Sciences/Cologuard require expensive centralized testing in an in-house lab\nEnables the sale of ColoAlert® internationally",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "89ef85b2-8646-40a9-bc11-9987fb4a6bcc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.04,
        "y": 0.55
      },
      "kind": "list",
      "text": "Developing next-gen product\nExpanding current test to add novel, proprietary mRNA biomarkers to increase the detection of advanced adenomas\nEarly detection of advanced adenomas (precancerous lesions) could drastically reduce or even eliminate cancer\nTwo ongoing clinical trials with data expected mid 2023; planning to initiate recruitment for FDA PMA pivotal study in H2 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c3146ce0-9e17-4f22-a388-8902acf5acdf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.04,
        "y": 0.0016
      },
      "kind": "list",
      "text": "Highly-differentiated flagship product (ColoAlert®)\nHighly efficacious, at-home, stool-based screening test for early colorectal cancer (CRC) detection\nCombines a FIT test for detection of human hemoglobin with the PCR results of specific tumor DNA markers\nMarketed as a CE-IVD product in Europe since 2021",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c9897be7-6103-49ac-88d7-b71cac539f67",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.37,
        "y": 0.55
      },
      "kind": "list",
      "text": "Strong intellectual property position\nValuable IP position, with new IP in development\nTrade secret portfolio",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd415bff-b881-4739-9801-6607923fff06",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.37,
        "y": 0.0016
      },
      "kind": "list",
      "text": "Significant market opportunity\n$10bn+ global CRC market (3rd most-commonly diagnosed cancer; 2nd leading cause of cancer death globally)\nAbility to move into large, adjacent areas, including pancreatic cancer and other GI cancers",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cdec8563-375c-4bf6-b657-eba0a57aae9d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.32,
        "x": 0.04,
        "y": 0.03
      },
      "kind": "title",
      "text": "Mainz Biomed Overview",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c3009ca9-e8e8-44e7-a989-7ace0368702f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "face0254-5b40-473b-90c2-212f0d353cb2",
      "evidence": "This slide is titled 'Mainz Biomed Overview' and contains a list/bullet points that summarize the company's key points, which is a common structure for an executive summary.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 25,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "82aba536-6cfb-4714-9432-b52a39ec7273",
      "evidence": "WHY (CRC need), HOW (innovative tests), WHAT (investment ask)",
      "position": 1,
      "objective": "Presenting a compelling investment opportunity",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}